SK Bioscience announced on the 31st that its consolidated operating (preliminary) results for the second quarter of this year recorded sales of 26.777 billion KRW and an operating loss of 19.94 billion KRW. Compared to the same period last year, sales increased by 1.1%, and the operating loss was reduced by 43.5%.
On a cumulative basis for the first half of the year, sales amounted to 49.048 billion KRW, with an operating loss of 48.042 billion KRW. This also represents a 4.2% increase in sales compared to the first half of last year, and a 25.5% decrease in the loss margin.
The company explained, "Sales of the shingles vaccine increased by 2.9 billion KRW compared to the previous year in the first half, and exports of the chickenpox vaccine also rose by 8.5 billion KRW year-on-year." They added, "Distribution sales of Sanofi vaccines also increased by 7 billion KRW in the second quarter, marking the beginning of full reflection."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
